Purpose: PARP plays an important role in DNA repair. Veliparib, a PARP inhibitor, enhances
the efficacy of platinum compounds and has been safely combined with carboplatin and …

Abstract Background This open-label Phase 3 trial (NCT02264990) evaluated the PARP
inhibitor, veliparib, combined with carboplatin/paclitaxel versus chemotherapy alone for first …

Introduction Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy
of DNA-damaging chemotherapeutic agents. The study objectives were to determine the …

PURPOSE Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with
evidence of DNA damage. This phase III study investigated the efficacy and safety of poly …

Objectives Both combinations of the PARP inhibitor veliparib plus platinum doublet
chemotherapy (CT), and the programmed death receptor-1 (PD-1) inhibitor nivolumab plus …

Introduction Tobacco-related NSCLC is associated with reduced survival and greater
genomic instability. Veliparib, a potent poly (adenosine diphosphate–ribose) polymerase …

Background We conducted a 2-part study to evaluate the incorporation of veliparib, a PARP
inhibitor, into chemoradiotherapy (CRT) for stage III non–small-cell lung cancer. Patients …

Purpose: This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP
inhibitor, combined with carboplatin and etoposide in patients with extensive-stage (ED) …

3049 Background: Veliparib (ABT-888, NSC 737664) is an orally available inhibitor of poly
(ADP-ribose) polymerase (PARP)-1 and-2: enzymes that recruit base excision repair …

Objectives Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in
preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the …